Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097398 - BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

Publication Number WO/2020/097398
Publication Date 14.05.2020
International Application No. PCT/US2019/060360
International Filing Date 07.11.2019
IPC
A61K 31/496 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/426 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
4261,3-Thiazoles
A61K 31/428 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
428condensed with carbocyclic rings
C07D 277/66 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
277Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60condensed with carbocyclic rings or ring systems
62Benzothiazoles
64with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
66with aromatic rings or ring systems directly attached in position 2
C07D 277/68 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
277Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60condensed with carbocyclic rings or ring systems
62Benzothiazoles
68with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 277/82 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
277Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60condensed with carbocyclic rings or ring systems
62Benzothiazoles
68with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
82Nitrogen atoms
Applicants
  • DANA-FARBER CANCER INSTITUTE, INC. [US]/[US]
  • HAO, Mingfeng [CN]/[US]
Inventors
  • HAO, Mingfeng
  • GRAY, Nathanael, S.
  • ZHANG, Tinghu
  • LIU, Yao
  • WEINSTOCK, David
  • LI, Loretta, Sze-mun
Agents
  • ZHANG, William, Wei
  • ALAM, Saad
  • ATTISHA, Michael, J.
  • AMUNDSEN, Eric, L.
  • BAKER, C., Hunter
Priority Data
62/757,13107.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
(FR) DÉRIVÉS BENZOTHIAZOLES ET DÉRIVÉS 7-AZA BENZOTHIAZOLES COMME INHIBITEURS DE LA JANUS KINASE 2 ET LEURS UTILISATIONS
Abstract
(EN)
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).
(FR)
La présente invention concerne des composés de Formule (I), et des sels, solvates, hydrates, polymorphes, co-cristaux, tautomères, stéréo-isomères, dérivés isotopiquement marqués pharmaceutiquement acceptables, et leurs promédicaments. Les composés selon l’invention peuvent être des inhibiteurs de kinase (par exemple, Janus kinase (JAK), par exemple, Janus kinase (2) (JAK2)). L’invention concerne également des compositions pharmaceutiques et des kits comprenant les composés décrits. L’invention concerne en outre des procédés d’utilisation des composés fournis, des compositions pharmaceutiques, et des kits (par exemple, pour traiter une maladie (par exemple, maladie proliférative) chez un sujet en ayant besoin).
Latest bibliographic data on file with the International Bureau